Sequential administration of cyclophosphamide and granulocyte-colony stimulating factor relieves impaired myeloid maturation in Felty's syndrome.
A patient with Felty's syndrome (FS) and persistent profound neutropenia developed recurrent infections and sepsis syndrome. No impairment of granulocyte-macrophage colony development was observed in vitro. Marrow morphology revealed an absence of mature neutrophil forms despite administration of granulocyte-colony stimulating factor (G-CSF). However, pretreatment with bolus cyclophosphamide (CY) permitted the growth factor to relieve this impairment of late myeloid maturation and resulted in a brisk, albeit short, burst of neutrophilia. This suggests that immune interference in myelopoiesis can be overcome by growth factor administration if immune activity is adequately dampened by immunosuppressive therapy.
Pixley
J S
JS
VAMC, Reno, NV.
Yoneda
K Y
KY
Manalo
P B
PB
D001853:Bone Marrow / Q000473:pathology*; D002454:Cell Differentiation / Q000187:drug effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005258:Felty Syndrome / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D006098:Granulocytes / Q000473:pathology; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D007165:Immunosuppression Therapy; D008264:Macrophages / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000150:complications; D009504:Neutrophils / Q000473:pathology
D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide